Adverum Biotechnologies (ADVM) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 1 Phase 2[2].
Trial NCT06856577[4] evaluates Ixo-vec in Neovascular Age-Related Macular Degeneration (nAMD) with a target enrollment of 284 participants. Trial NCT07482176[5] evaluates Ixo-vec in Neovascular Age-Related Macular Degeneration (nAMD) with a target enrollment of 284 participants.
No Form 4 insider filings for ADVM were recorded at the SEC in the past 30 days[6].